Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia

Launched by HIROSHIMA UNIVERSITY HOSPITAL · May 9, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called PPMX-T003 for patients with aggressive NK-cell leukemia, a serious type of blood cancer. The goal of the trial is to check how safe the treatment is, how well it works, and how the body processes the drug. This is a Phase I/II study, which means it’s one of the first steps in testing a new treatment in people. The trial is currently recruiting participants of all genders, aged between 18 and 65 years old, who have been diagnosed with aggressive NK-cell leukemia, whether it’s their first time being treated or if it has come back after previous treatment.

To join the study, patients must have a confirmed diagnosis of aggressive NK-cell leukemia according to specific medical guidelines. However, those who are eligible for standard chemotherapy treatments cannot participate. If you take part in this trial, you can expect to receive the new treatment and be closely monitored by the medical team for any side effects and to see how effective the treatment is. This is an important step in exploring new therapies for a challenging condition, and your participation could help advance medical knowledge and treatment options for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed with ANKL (regardless of whether the disease is first or recurrent) based on diagnostic criteria developed with reference to the World Health Organization (WHO) 4th edition (2017) criteria.
• Exclusion Criteria:
• • Patients eligible to receive chemotherapy as treatment for ANKL